Unlock instant, AI-driven research and patent intelligence for your innovation.

Pyrimidine derivative

一种二氢嘧啶、吡啶的技术，应用在新型嘧啶衍生物领域，能够解决血栓症风险提高、增加心血管疾病等问题

Active Publication Date: 2018-06-08
ASKA PHARMACEUTICAL CO LTD
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among the agents that selectively inhibit COX-2, although the production of PGI2, which has vasodilation and platelet aggregation, is inhibited, COX-1 catalyzes and does not inhibit thromboxane A2 (TXA2), which causes vasoconstriction and platelet aggregation. Therefore, the risk of thrombosis is considered to be increased, which in turn increases the risk of cardiovascular disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrimidine derivative
  • Pyrimidine derivative
  • Pyrimidine derivative

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0431] Hereinafter, the present invention will be described in more detail based on examples, but the present invention is not limited by these examples. In addition, regarding the example compounds, Table 1-1 to Table 1-18 show chemical structural formulas.

reference example 1

[0432] Reference Example 1: N-(4-chloro-3-cyanobenzyl)-2,2-dimethylpropanamide

[0433] [chemical 14]

[0434]

[0435] To a solution of 2.44 g of 5-aminomethyl-2-chlorobenzonitrile in 50 mL of dichloromethane was added 11 mL of N,N-diisopropylethylamine. Under ice cooling, pivaloyl chloride was added. Return to room temperature and stir for 3 hours. The reaction solution was poured into water, and chloroform was added to separate the organic layer. The organic layer was washed with saturated brine. After drying the organic layer over sodium sulfate, the solvent was distilled off. Silica gel column chromatography was carried out to obtain 3.28 g of the title compound.

[0436] 1 H-NMR (CDCl 3 ,δ):1.24(9H,s),4.43(2H,d,J=5.9Hz),6.11(1H,brs),7.4-7.6(3H,m)

[0437] MS(m / z):250(M + ).

reference example 2

[0438] Reference Example 2: N-(3-formamidoyl)-4-chlorobenzyl)-2,2-dimethylpropanamide hydrochloride

[0439] [chemical 15]

[0440]

[0441] A suspension of 2.09 g of ammonium chloride in 49 mL of toluene was cooled with ice under nitrogen substitution, and 22 mL of a toluene solution (1.8 M) of trimethylaluminum was added. Return to room temperature and stir for 1 hour. 3.26 g of N-(4-chloro-3-cyanobenzyl)-2,2-dimethylpropanamide was added, followed by washing with 5 mL of toluene. The external temperature was stirred overnight at 80°C. The reaction solution was ice-cooled, and 105 mL of methanol was added. The reaction solution was stirred at 80° C. for 30 minutes. After returning to room temperature and stirring for 18 minutes, the mixture was stirred under ice cooling for 27 minutes. The insoluble matter was filtered off, and the solvent was distilled off from the filtrate to obtain 3.91 g of the title compound. The resulting compound was used in the next reaction...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A compound represented by formula (1) or salt thereof which has an inhibitory effect on mPGES-1, and is useful as an active ingredient for a medicinal drug for preventing and / or treating a disease such as inflammation, pain, rheumatism, or the like (X represents a carbonyl group or a sulfonyl group; R1 represents a hydrogen atom, a halogen atom, an alkyl group, an alkanoyl group, a cyano group, ora carboxyl group; R2 represents an alkyl group, a carbocyclic group, or a heterocyclic group; R3 represents a hydrogen atom or 1-3 substituents; R4 and R5 represent a hydrogen atom, a halogen atom, or an alkyl group; and R6 represents an alkyl group or an alkoxy group).

Description

technical field [0001] The present invention relates to novel pyrimidine derivatives. More specifically, it relates to pyrimidine derivatives which have mPGES-1 inhibitory activity and are useful as active ingredients of drugs for the prevention and / or treatment of diseases such as inflammation, pain, and rheumatism. Background technique [0002] Prostaglandin E2 (PGE2) participates in inflammation, pain and fever through PGE receptors, and can inhibit inflammation by inhibiting the production of PGE2. Nonsteroidal anti-inflammatory drugs (NSAIDs) exert anti-inflammatory effects by inhibiting cyclooxygenase (COX) in the upstream of the prostaglandin biosynthesis pathway, but completely inhibit the production of prostaglandins through the participation of COX in the prostaglandin biosynthesis pathway The downstream biosynthetic pathway, therefore, as a side effect, gastric mucosal lesions may occur due to the secretion of gastric mucus and the inhibition of gastric mucos...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D239/36A61K31/506A61P9/10A61P17/00A61P19/02A61P25/00A61P25/28A61P27/02A61P29/00A61P35/00A61P43/00C07D401/04C07D409/04
CPCA61K31/506C07D401/04C07D239/36C07D409/04C07D401/14C07D405/14C07D403/04C07D417/04A61P13/02A61P13/04A61P13/08A61P13/10A61P17/00A61P19/02A61P25/00A61P25/04A61P25/28A61P27/02A61P29/00A61P35/00A61P43/00A61P9/10C07D401/10C07D401/12
Inventor 冈田亮中野洋一能势卓西本恭博前田智史
Owner ASKA PHARMACEUTICAL CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com